Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $12.9 billion.

  • Genmab A's Liabilities and Shareholders Equity rose 10070.16% to $12.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $32.9 billion, marking a year-over-year increase of 8391.11%. This contributed to the annual value of $12.9 billion for FY2025, which is 10070.16% up from last year.
  • Latest data reveals that Genmab A reported Liabilities and Shareholders Equity of $12.9 billion as of Q4 2025, which was up 10070.16% from $7.0 billion recorded in Q3 2025.
  • Genmab A's Liabilities and Shareholders Equity's 5-year high stood at $12.9 billion during Q4 2025, with a 5-year trough of $5.2 billion in Q4 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $6.4 billion (2024), whereas its average is $7.0 billion.
  • The largest annual percentage gain for Genmab A's Liabilities and Shareholders Equity in the last 5 years was 10070.16% (2025), contrasted with its biggest fall of 1659.45% (2025).
  • Quarter analysis of 3 years shows Genmab A's Liabilities and Shareholders Equity stood at $5.2 billion in 2023, then rose by 22.59% to $6.4 billion in 2024, then surged by 100.7% to $12.9 billion in 2025.
  • Its Liabilities and Shareholders Equity was $12.9 billion in Q4 2025, compared to $7.0 billion in Q3 2025 and $6.5 billion in Q2 2025.